Moderate supplementation with natural alpha-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation

Atherosclerosis. 1999 Nov 1;147(1):177-85. doi: 10.1016/s0021-9150(99)00169-0.


Previous studies have shown that oral administration of 300 mg alpha-tocopherol/day to healthy volunteers decreases platelet function and enhances their sensitivity to the platelet inhibitor, prostaglandin E(1), when full dose-response curves to a range of agonist concentrations are made. In this study, the effects of oral doses of natural alpha-tocopherol (75, 200 and 400 IU/day) were studied in order to determine whether the same effects might be achieved with lower intakes of vitamin E and whether inhibition is related to the platelet levels of the antioxidant in platelet membranes. Twenty two subjects undertook the supplementation regime, divided into three units of 2 weeks, each cycling through each of the dosages. The results show that uptake of vitamin E by the platelets was optimal at 75 IU/day, correlating with the maximal influence on platelet aggregation and platelet responsiveness to inhibition by PGE1, increased supplemental levels exerting no greater effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Administration, Oral
  • Adult
  • Alprostadil / pharmacology
  • Blood Platelets / metabolism
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lipids / blood
  • Lipoproteins / blood
  • Lipoproteins, LDL / blood
  • Lipoproteins, LDL / drug effects
  • Lipoproteins, LDL / metabolism*
  • Male
  • Middle Aged
  • Oxidation-Reduction / drug effects
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology
  • Vitamin E / administration & dosage*
  • Vitamin E / blood
  • beta-Thromboglobulin / metabolism


  • Lipids
  • Lipoproteins
  • Lipoproteins, LDL
  • Platelet Aggregation Inhibitors
  • beta-Thromboglobulin
  • Vitamin E
  • Adenosine Triphosphate
  • Alprostadil